Novartis

FDA sends letter to Novartis over 'significant' Kymriah manufacturing safety concerns ENDPOINTS15:26
Novartis’s fabhalta reaches first stop on regulatory journey with PNH nod Scrip Pharma Intelligence17:30
Novartis' Pluvicto readout is causing trouble for Eli Lilly’s $1.4B radiotherapy buy FierceBiotech11:22
Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfalls FiercePharma09:33
Novartis unveils new brand identity after Sandoz spinoff ENDPOINTS07:11
Blackstone eyes sale of anthos therapeutics in potential billion-dollar deal Private Equity Insights07:48
Novartis: Post Investor Day, Higher Guidance Priced In Seeking Alpha05:43

Latest News

In the last 7 days
In brief: Novartis welcomes "significant milestone" for Kisqali London South East15:10 8-Dec-23
Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case BioSpace11:33 8-Dec-23
Novartis preps Kisqali for FDA; Ventyx cuts 20% of workers; Keytruda plus Lenvima hits PhIII setback ENDPOINTS11:01 8-Dec-23
Intrigued by Novartis and Lilly deals, investors pour money into radiopharmaceuticals FierceBiotech10:10 8-Dec-23
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of… BioSpace10:02 8-Dec-23
SABCS: As Lilly showdown nears, Novartis gives another look at Kisqali data in early breast… FiercePharma09:26 8-Dec-23
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of… GlobeNewswire (Press Release)09:16 8-Dec-23
Fierce Pharma Asia—WuXi Bio's plunge; Daiichi-Novartis $182M settlement; Merck KGaA's Abbisko… FiercePharma08:25 8-Dec-23
Global Tyrosine Kinase Inhibitors Market Report 2023-2028, Featuring Profiles of Major Players… PR Newswire (Press Release)14:15 7-Dec-23
Dry Eye Disease Market to Register Immense Growth During the Study Period (2019–2032), Estimates DelveInsight | Leading … GlobeNewswire (Press Release)13:05 7-Dec-23
Novartis makes investment in AI firm Yseop for clinical trial writing FierceBiotech09:36 7-Dec-23
Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfalls FiercePharma09:33 7-Dec-23
Kymriah GMP issues in NJ led to FDA letter for Novartis BioProcess Insider08:26 7-Dec-23
Novartis invests $85m in China radioligand facility BioProcess Insider05:23 7-Dec-23
Novartis’s Fabhalta Reaches First Stop On Regulatory Journey With PNH Nod Scrip Pharma Intelligence17:30 6-Dec-23
US FDA approves Novartis’ factor B inhibitor for rare blood disease BioWorld17:06 6-Dec-23
Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case FiercePharma11:20 6-Dec-23
Radiopharmaceutical Leader ITM Gets A Burst Of Energy – And Weighs Up Going Public Scrip Pharma Intelligence11:14 6-Dec-23
FDA endorses Novartis' 'pipeline in a pill,' granting first nod for potential blockbuster… FiercePharma11:10 6-Dec-23
SABCS: Handing Novartis a win, Lilly's Verzenio barely misses overall survival goal in… FiercePharma10:09 6-Dec-23
Novartis Wins FDA Approval for Oral Monotherapy for Rare Blood Disorder BioSpace09:43 6-Dec-23
Novartis secures first-of-a-kind haematology approval European Pharmaceutical Review09:05 6-Dec-23
FDA approves Novartis drug for rare blood disorder ENDPOINTS09:04 6-Dec-23
Novartis receives FDA approval for Fabhalta to treat PNH in adults Pharmaceutical Business Review08:56 6-Dec-23
Novartis' Rare Blood Disorder Therapy Scores FDA Approval Benzinga08:45 6-Dec-23
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug Zacks08:36 6-Dec-23
Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH PMLiVE07:49 6-Dec-23
Daiichi Sankyo unit claims $182m in Novartis patent dispute pharmaphorum06:44 6-Dec-23
FDA approves Novartis’ Fabhalta for PNH treatment Pharmafile06:39 6-Dec-23
Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH pharmaphorum06:04 6-Dec-23
Capmatinib hydrochloride by Novartis for Hepatocellular Carcinoma: Likelihood of Approval Pharmaceutical Technology20:47 5-Dec-23
Batoprotafib by Novartis for Gastrointestinal Stromal Tumor (GIST): Likelihood of Approval Pharmaceutical Technology20:16 5-Dec-23
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of… GlobeNewswire (Press Release)19:19 5-Dec-23
FDA sends letter to Novartis over 'significant' Kymriah manufacturing safety concerns ENDPOINTS15:26 5-Dec-23
HCMC University Medicines Centre to manage transplantation by UMC Care mobile application Viet Nam News11:56 5-Dec-23
Novartis' Pluvicto readout is causing trouble for Eli Lilly’s $1.4B radiotherapy buy FierceBiotech11:22 5-Dec-23
Mark Vineis appointed as the new Country President of Novartis Canada BioSpace09:29 5-Dec-23
Novartis follows Pfizer, GSK, J&J and Sanofi as it launches a fresh corporate rebranding FiercePharma08:33 5-Dec-23
Blackstone Eyes Sale of Anthos Therapeutics in Potential Billion-Dollar Deal Private Equity Insights07:48 5-Dec-23
Roche bounces back in PIK3 with inavolisib data pharmaphorum06:30 5-Dec-23
Novartis: Post Investor Day, Higher Guidance Priced In Seeking Alpha05:43 5-Dec-23
DFT-383 by Novartis for Cystinosis: Likelihood of Approval Pharmaceutical Technology01:03 5-Dec-23
Ruxolitinib phosphate by Novartis for Oral Cavity (Mouth) Cancer: Likelihood of Approval Pharmaceutical Technology23:42 4-Dec-23
Ruxolitinib phosphate by Novartis for Laryngeal Cancer: Likelihood of Approval Pharmaceutical Technology23:42 4-Dec-23
Ruxolitinib phosphate by Novartis for Hypopharyngeal Cancer: Likelihood of Approval Pharmaceutical Technology23:42 4-Dec-23
Licogliflozin by Novartis for Metabolic Dysfunction-Associated Steatohepatitis (MASH):… Pharmaceutical Technology21:18 4-Dec-23
Remibrutinib by Novartis for Hidradenitis Suppurativa: Likelihood of Approval Pharmaceutical Technology20:58 4-Dec-23
Remibrutinib by Novartis for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of… Pharmaceutical Technology20:58 4-Dec-23
Fujifilm makes $200M manufacturing investment while Novartis pours $80M+ into China facility ENDPOINTS14:49 4-Dec-23
AI becoming embedded in R&D, in this week’s R&D Power Index Drug Discovery & Development13:34 4-Dec-23
Capmatinib hydrochloride by Novartis for Metastatic Melanoma: Likelihood of Approval Pharmaceutical Technology12:19 4-Dec-23
Ruxolitinib phosphate by Novartis for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval Pharmaceutical Technology12:09 4-Dec-23
Ruxolitinib phosphate by Novartis for Oropharyngeal Cancer: Likelihood of Approval Pharmaceutical Technology12:09 4-Dec-23
Novartis is building a new radioligand plant in China STAT09:50 4-Dec-23
Novartis Voluntarily Recalls Two Lots of Sandimmune Oral Solution, 100 mg/mL PharmTech.com09:30 4-Dec-23
KRAS Inhibitor Market to grow significantly by 2032 | Novartis, Roche, Genentech, Verastem… Industry Today07:46 4-Dec-23
Novartis unveils new brand identity after Sandoz spinoff ENDPOINTS07:11 4-Dec-23
Latex Allergy Market May See a Big Move| Alcon Vision, Novartis, Sanofi Industry Today05:43 4-Dec-23
NAFDAC alerts public to Parallel importation of unregistered Novartis Prescription Medicines at Muritala Mohammed… Nairametrics05:10 4-Dec-23
Our next era Novartis (Press Release)01:17 4-Dec-23
How I found my true purpose at Novartis Novartis (Press Release)01:17 4-Dec-23
Belonging here: How Novartis helped me come out as a transgender woman Novartis (Press Release)01:17 4-Dec-23
Mentoring matters: how we grow together at Novartis Novartis (Press Release)01:17 4-Dec-23
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and… Novartis (Press Release)01:07 4-Dec-23
Quick Listen: Scrip's Five Must-Know Things Scrip Pharma Intelligence00:13 4-Dec-23
Novartis' Cosentyx secures reimbursement as 1st-line treatment for ankylosing spondylitis Korea Biomedical Review21:09 3-Dec-23
In the last month
Pharma Heads Pass Leadership Baton BioSpectrum Asia23:59 1-Dec-23
Novartis taps ‘Sopranos’ actress for new multiple sclerosis Kesimpta campaign ENDPOINTS12:54 1-Dec-23
Novartis expands radiotherapy manufacturing network with $85M plant in China FiercePharma11:13 1-Dec-23
Novartis to build plant in Zhejiang, to speed up cancer treatment SHINE04:42 1-Dec-23
Dezeen Debate features "impressive" Basel pavilion Dezeen14:39 30-Nov-23
Atropos Health Forms Life Science Advisory Board, Increasing Commitment to Accelerated Drug… Business Wire (Press Release)09:50 30-Nov-23
Tendinopathy Market to Register Incremental Growth During the Study Period (2019–2032), Estimates DelveInsight |… GlobeNewswire (Press Release)13:01 29-Nov-23
Researchers Announce Positive Trial Data for the Use of Remibrutinib In Chronic Spontaneous Urticaria Pharmacy Times11:53 29-Nov-23
Novartis Raises Growth Target, Trims Pipeline Under ‘Pure-Play’ Strategy BioSpace07:28 29-Nov-23
Novartis Has A New Goal: $2bn Peak Sales Per Product Scrip Pharma Intelligence17:26 28-Nov-23
Novartis raises sales growth target Reuters - YouTube12:35 28-Nov-23
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy Zacks12:05 28-Nov-23
Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off Benzinga11:28 28-Nov-23
Novartis execs highlight progress of slimmer pipeline after Sandoz spinoff ENDPOINTS11:10 28-Nov-23
Novartis dials up midterm sales projection, fleshes out Kisqali's $7B-plus goal FiercePharma11:00 28-Nov-23
Novartis bought his first startup for $3.9 billion. Now this physicist is trying to sell Europe … Fortune10:29 28-Nov-23
Novartis (NYSE:NVS) Boosts Sales Growth Expectations Through 2027 TipRanks08:16 28-Nov-23
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of… Novartis (Press Release)06:38 28-Nov-23
Novartis raises sales growth target to 5% a year RTE05:40 28-Nov-23
Poisoning Treatment Market Projected to Show Strong Growth| BTG, Novartis, Bristol-Myers Squibb Industry Today05:06 28-Nov-23
Novartis Raises Annual Sales Growth Forecast After Restructuring BNN Bloomberg04:30 28-Nov-23
Novartis lifts sales growth target to 5% per year through 2027 Irish Examiner03:05 28-Nov-23
Novartis Ups Mid-Term Targets The Wall Street Journal02:47 28-Nov-23
Novartis Raises Mid-Term Sales Growth Targets MarketWatch01:45 28-Nov-23
Novartis aims for 5% annual sales growth through 2027 Reuters01:30 28-Nov-23
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust … GlobeNewswire (Press Release)01:02 28-Nov-23
Novartis Recalls Sandimmune Oral Solution RTT News00:30 28-Nov-23
Novartis pulls 2 batches of Sandimmune after spotting crystal formations—again FiercePharma15:30 27-Nov-23
Freshfields Advises Novartis on Its Exclusive License Agreement with Legend Biotech Freshfields (Press Release)11:15 27-Nov-23
Novartis recalls Sandimmune oral solution over crystallisation issues Pharmaceutical Technology05:14 27-Nov-23
Synthetic Hormones Market Analysis Report 2023-2033, Featuring Profiles of Eli Lilly, Pfizer, Ferring, Merck, Novo… GlobeNewswire (Press Release)04:31 27-Nov-23
Global Pain Management Drugs and Devices Market Report 2023 - Focus on Key Players in Pain… PR Newswire (Press Release)17:31 24-Nov-23
Novartis Urges Court to Hand It Quick Win in Drug Price Battle Bloomberg Law11:51 24-Nov-23
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution,… BioSpace10:25 24-Nov-23
Novartis sees highest patent filings and grants during August in Q3 2023 Pharmaceutical Technology08:16 24-Nov-23
AMDL Circle and Iart wrap Basel pavilion in energy-neutral media facade Dezeen07:35 24-Nov-23
Nasal Drug Delivery Technology Market – Major Technology Giants in Buzz Again | Merck & Co.,… Industry Today04:13 23-Nov-23
Novartis drops subpoena request in trade-secret spat with Takeda FiercePharma11:18 22-Nov-23
Novartis Pharmaceuticals Drops Trade Secret Spat With Takeda Bloomberg Law09:25 22-Nov-23
Novartis Looks To Lead CAR-T Expansion Into Autoimmune Disease Scrip Pharma Intelligence11:48 21-Nov-23
The Zacks Analyst Blog Highlights Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex… Zacks09:04 21-Nov-23
Earnings call: Legend Biotech Reports Q3 Results, Announces Novartis Licensing Agreement Investing.com20:35 20-Nov-23
Novartis Pharms. Corp. v. Alembic Pharms. Ltd. - Entresto® (Sacubitril/Valsartan) JD Supra16:20 20-Nov-23
Global Ophthalmic Drugs Market Report 2024-2034: Profiles of Leading Players Including AbbVie,… PR Newswire (Press Release)11:16 20-Nov-23
Legend Biotech highlights Novartis deal worth up to $1.11BN alongside 3Q results Proactive Investors (US)07:20 20-Nov-23
Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US… GlobeNewswire (Press Release)04:32 20-Nov-23
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH GlobeNewswire (Press Release)01:18 20-Nov-23
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal Seeking Alpha02:11 19-Nov-23
A Comprehensive Study Exploring Deep Vein Thrombosis Treatment Market | Key Players Hikma… Industry Today23:59 18-Nov-23

      
            
      
    view more headlines
   
      
      
      
8 Dec 15:10
   

About our Novartis news

Latest news for Novartis, a global healthcare company based in Switzerland specialising in pharmaceuticals, including updates on company and product news.

Novartis

Latest News

About our Novartis news

Pharmaceuticals Top Stories

Business Top Stories